Compounded Semaglutide UK: Legal Status, Pharmacies & 2026 MHRA Position

Overview

Semaglutide, sold as Ozempic (diabetes) and Wegovy (weight management), has transformed how clinicians approach obesity treatment in the UK. Yet NHS access remains tightly rationed, and the brand-name products carry significant monthly costs when accessed privately. Into this gap has stepped compounded semaglutide — medication prepared by specialist pharmacies using the active ingredient outside the standard licensed supply chain. In the UK this practice is governed by different rules than in the United States, and the MHRA has expressed serious concerns. This guide explains the legal landscape, the pharmacies involved, comparative costs, and what UK patients should understand before considering compounded semaglutide in 2026.

What Is Compounded Semaglutide?

Compounded semaglutide refers to semaglutide that has been prepared — or "compounded" — by a pharmacy outside the standard licensed manufacturing process. Rather than dispensing the commercially produced Ozempic or Wegovy pen device, a compounding pharmacy mixes the active pharmaceutical ingredient (API) into a preparation, typically a multi-dose vial for subcutaneous injection. The finished product is not manufactured to the same regulatory standards as a licensed medicine and does not undergo the same batch testing, stability validation, or pharmacovigilance obligations required of brand-name products approved by the MHRA. Compounded preparations can vary considerably in terms of concentration, excipients, and storage requirements, which introduces variables that do not exist with standardised licensed products. In some cases, UK suppliers have also offered semaglutide analogues or salts — such as semaglutide acetate — that differ chemically from the approved molecule used in Ozempic and Wegovy, raising additional safety questions.

UK Legal Status: Specials vs Authorised Medicines

In the United States, compounding pharmacies can operate under FDA 503B "outsourcing facility" status, allowing them to produce large batches of compounded medicines for distribution across the healthcare system — particularly when a drug appears on the FDA's drug shortage list. The UK has no direct equivalent to 503B. Instead, UK law permits a narrower form of compounding under the "Specials" regime governed by Regulation 167 of the Human Medicines Regulations 2012. A "Special" is an unlicensed medicinal product that a UK-registered pharmacy (holding a Manufacturer's Specials Licence, or MS licence) can prepare for an individual named patient when no licensed product is suitable for that patient's clinical need. This is a critical distinction: a Special must be prescribed for a specific patient by a registered prescriber who has determined that no licensed alternative meets that patient's needs. It cannot be pre-made in large batches and sold speculatively. The MHRA has been clear that mass-produced compounded semaglutide falls outside this framework and is not legally authorised for sale in the UK. Many online operations advertising compounded semaglutide are therefore operating outside UK law, regardless of where they are based.

MHRA Position and 2025–2026 Regulatory Updates

Throughout 2024 and into 2025–2026, the MHRA has intensified its scrutiny of unlicensed semaglutide products circulating in the UK market. The agency issued a formal warning in 2024 alerting patients to counterfeit and substandard semaglutide products being sold online and through unregistered clinics. The MHRA highlighted specific risks including incorrect dosing instructions, contaminated API, improper storage during transit, and lack of batch traceability. In response to the ongoing Wegovy supply shortage that plagued the UK market during 2023–2024, the MHRA temporarily updated its guidance on Specials to clarify that supply shortage alone does not automatically create a "clinical need" justification for prescribing unlicensed alternatives. As of early 2026, the MHRA has not moved to create a formal pathway equivalent to FDA 503B, nor has it authorised any compounded semaglutide product. The agency continues to advise that patients seek licensed GLP-1 therapies through legitimate NHS or private prescribing routes. Healthcare professionals who prescribe compounded semaglutide expose themselves to professional conduct risks under General Medical Council (GMC) and General Pharmaceutical Council (GPhC) frameworks.

Which UK Pharmacies and Clinics Offer It?

Despite the MHRA's position, a number of UK-based and overseas online services have been offering what they describe as compounded or "pharmaceutical-grade" semaglutide to UK patients. These typically operate through one of three models: private online clinics that issue prescriptions and partner with compounding pharmacies; direct-to-consumer websites shipping product from overseas jurisdictions (notably Turkey, India, or the US); and domestic pharmacies holding Specials licences that prepare named-patient prescriptions. None of the major regulated UK pharmacy chains — including Boots, Lloyds Pharmacy, or Pharmacy2U — offer compounded semaglutide. Pharmacy2U, which has been involved in distributing NHS-prescribed Wegovy through specialist tier-3 pathways, stocks only the licensed Novo Nordisk product. Patients considering private compounding routes should verify that any prescribing clinic is CQC-registered, that the prescriber holds a valid GMC or NMC registration, and that the compounding pharmacy holds a valid GPhC registration and MS licence. The GPhC's online register allows public verification. Purchasing from unregistered overseas websites carries significant legal and health risks.

Cost Comparison: NHS Wegovy vs Private Compounded

For patients who qualify through the NHS, Wegovy (semaglutide 2.4 mg) is available free at the point of use, though access is gated behind strict eligibility criteria and long waiting lists. Private access to licensed Wegovy from a regulated UK clinic typically costs between £200 and £350 per month depending on provider and dose stage. Compounded semaglutide, where available through private UK-linked routes, is marketed at lower price points — commonly £150 to £250 per month for vials covering four to five weeks of treatment at maintenance doses. However, this headline cost saving must be weighed against significant uncertainties: product potency may not match the label claim, sterility cannot be guaranteed by the patient, and there is no pharmacovigilance safety net if an adverse reaction occurs. Some providers charge additional consultation, delivery, and reconstitution-supply fees (bacteriostatic water, syringes) that raise the effective monthly cost. For patients who cannot access NHS Wegovy and cannot afford licensed private supply, the appeal of compounded semaglutide is understandable — but the MHRA's warnings about substandard products are a genuine patient-safety concern rather than merely a regulatory technicality.

NHS Eligibility vs Private Access: BMI Thresholds

NHS access to semaglutide for weight management (Wegovy) is governed by NICE Technology Appraisal TA875, which the NHS implemented through a specialist weight management service pathway. To qualify, patients must be referred to a Tier 3 weight management service, have a BMI of 35 kg/m² or above (or 32.5 for certain South Asian, Chinese, or other ethnicities where lower thresholds apply) alongside at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea. The NHS also requires that Wegovy is used as part of a multi-component programme including dietary, behavioural, and physical activity components — it cannot be prescribed as a standalone treatment. This means patients with a BMI of 30–34.9 kg/m², or those without eligible comorbidities, do not currently qualify for NHS Wegovy regardless of their clinical need or GP support. Private clinics, by contrast, typically apply their own eligibility criteria; many prescribe semaglutide to patients with a BMI of 27 or above with comorbidities, or 30 and above without. This gap in NHS eligibility is a primary driver of demand for both private licensed semaglutide and compounded alternatives.

Safety Considerations and MHRA Concerns

The MHRA's concerns about compounded semaglutide are not theoretical. In 2024, the agency identified multiple cases of adverse reactions linked to products that analysis showed to be incorrectly dosed — with some vials containing several times the stated dose and others being significantly sub-potent. The agency has also flagged the use of semaglutide salts and analogues (particularly semaglutide acetate rather than the approved base form) in some compounded products; these variants have not undergone the clinical testing required to establish their safety and efficacy in humans. Additional risks include contamination during compounding, inadequate storage conditions during shipping, and errors in reconstitution by patients who are inexperienced with injectable medications. From a clinical safety standpoint, GLP-1 receptor agonists carry established risks including nausea, vomiting, gallbladder disease, pancreatitis, and — based on rodent data — a theoretical risk of medullary thyroid carcinoma. These risks are manageable under medical supervision with a licensed product and a registered prescriber, but become harder to monitor and respond to in compounded-product contexts where product quality and supply continuity are unreliable.

• Potency uncertainty: compounded vials may be over- or under-dosed relative to the label claim
• Sterility risk: non-GMP manufacture does not guarantee sterile product
• Chemical variants: semaglutide acetate and other salts are not equivalent to approved semaglutide
• No pharmacovigilance: adverse events from unlicensed products are not systematically tracked
• Import legality: ordering from overseas pharmacies may constitute unlicensed importation
• Professional risk: prescribers face potential GMC/GPhC sanctions for prescribing outside guidelines

Alternatives for UK Patients Who Cannot Access Wegovy

For UK patients who do not meet NHS eligibility criteria and are concerned about the risks of compounded semaglutide, several legitimate alternatives exist within the licensed healthcare pathway. Mounjaro (tirzepatide), a dual GIP/GLP-1 agonist, received NICE approval for weight management in late 2024 under TA1026 and is being rolled out through NHS specialist services with slightly different eligibility criteria to Wegovy — though similarly restricted. Privately, tirzepatide via licensed UK suppliers is available at comparable or slightly lower cost than Wegovy for some dose stages. Orlistat, a lipase inhibitor, remains available on NHS prescription for patients with BMI ≥28 with comorbidities or ≥30 without, offering a licensed lower-cost option. Behavioural weight management programmes, including the NHS Digital Weight Management Programme, are accessible through GP referral without BMI restrictions in some integrated care systems. Patients may also consider appealing their GP for NHS semaglutide access through Individual Funding Requests (IFRs) if their clinical situation is exceptional. Engaging with a private obesity specialist — a Tier 4 NHS consultant or equivalent private physician with a Certificate of Eligibility for Specialist Registration (CESR) in endocrinology or bariatrics — can help patients navigate available options including the expanding range of licensed GLP-1 therapies reaching the UK market.

References

1. MHRA Warning on Fake and Unlicensed Semaglutide Products (2024)
2. NICE Technology Appraisal TA875: Semaglutide for Managing Overweight and Obesity (2023)
3. Human Medicines Regulations 2012 — Regulation 167: Exemptions for Pharmacists (2012)
4. Semaglutide 2·4 mg once a week in adults with overweight or obesity (STEP 1 trial) (2021) — PubMed
5. GLP-1 receptor agonists and the risk of thyroid cancer: a systematic review (2022) — PubMed
6. NHS England: Wegovy (semaglutide) for Specialist Weight Management Services (2023)